SAR113244

DRUG2 trials

Sponsors

Sanofi

Conditions

Systemic Lupus Erythematosus

Phase 1

Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients

CompletedNCT02321709

SanofiSystemic Lupus Erythematosus

Start: 2014-11-30End: 2016-03-31Updated: 2016-05-02

Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients

WithdrawnNCT02331810

SanofiSystemic Lupus Erythematosus

Start: 2016-04-30End: 2017-05-31Updated: 2016-06-03